Search results

640 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
Research recommendations Remove Research recommendations filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter

Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

In development [GID-TA10105] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

In development [GID-TA10089] Expected publication date: 15 November 2017

Type

Technology appraisal guidance

Status

In development
DHT pilot: myCOPD for self-management of chronic obstructive pulmonary disease (COPD)

In development [GID-MT531] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

In development [GID-TA10527] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 02 March 2021

Type

Antimicrobial prescribing guideline

Status

In development
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

In development [GID-TA10458] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Eculizumab for treating relapsing neuromyelitis optica [ID1271]

In development [GID-TA10469] Expected publication date: 02 September 2020

Type

Technology appraisal guidance

Status

In development
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340

In development [GID-TA10313] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179

In development [GID-TA10450] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]

In development [GID-TA10742] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]

In development [GID-TA10524] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]

In development [GID-TA10430] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea ID1065

In development [GID-TA10385] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Synergo for non-muscle-invasive bladder cancer

In development [GID-MT553] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712]

In development [GID-TA10572] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

Proposed [GID-TA10598] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

In development [GID-TA10342] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

In development [GID-TA10495] Expected publication date: 18 August 2021

Type

Technology appraisal guidance

Status

In development
Tebentafusp for treating metastatic HLA-A*02:01 positive uveal melanoma (ID1441)

In development [GID-TA10428] Expected publication date: 04 May 2022

Type

Technology appraisal guidance

Status

In development
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]

Proposed [GID-TA10552] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509

In development [GID-TA10413] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]

Proposed [GID-TA10691] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

Proposed [GID-TA10694] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Retifanlimab for treating advanced anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

Proposed [GID-TA10698] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Etranacogene dezaparvovec for treating haemophilia B [ID3812]

Proposed [GID-TA10699] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

Proposed [GID-TA10702] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eptinezumab for preventing migraine [ID3803]

Proposed [GID-TA10677] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gefapixant for treating refractory chronic cough [ID3789]

Proposed [GID-TA10678] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for general anaesthesia [ID3796]

Proposed [GID-TA10679] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]

Proposed [GID-TA10680] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

Proposed [GID-TA10682] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

Proposed [GID-TA10684] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

Proposed [GID-TA10683] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

Proposed [GID-TA10723] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]

Proposed [GID-TA10725] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]

Proposed [GID-TA10726] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]

Proposed [GID-TA10632] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID3775]

In development [GID-TA10636] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

Proposed [GID-TA10574] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Type

Technology appraisal guidance

Status

In development
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

In development [GID-TA10254] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]

In development [GID-TA10399] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Luspatercept for treating beta-thalassaemia ID1554

In development [GID-TA10506] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Kidney transplantation (rejection) - everolimus [ID117]

In development [GID-TAG241] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

In development [GID-MT130] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Selumetinib for treating differentiated thyroid cancer ID1079

In development [GID-TA10207] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

In development [GID-TA10249] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
NY-ESO-1 T-cells for treating synovial sarcoma ID1286

In development [GID-TA10205] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development